Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-04-10
2010-12-28
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S254050, C514S254070, C514S314000, C514S326000, C544S121000, C544S129000, C544S363000, C544S370000, C546S175000, C546S205000
Reexamination Certificate
active
07858629
ABSTRACT:
Certain novel substituted imidazole 4-carboxamides are ligands of the human cholecystokinin receptor and, in particular, are selective ligands of the human cholecystokinin-1 receptor (CCK-1R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of CCK-1R, such as obesity, and diabetes.
REFERENCES:
patent: 6960601 (2005-11-01), Smith et al.
patent: 2004/0063691 (2004-04-01), Smith et al.
patent: 2005/0054679 (2005-03-01), Kruse et al.
patent: 2005/0124660 (2005-06-01), Antel et al.
patent: 2005/0197377 (2005-09-01), Breitenbucher et al.
patent: 2005/0256167 (2005-11-01), Smith et al.
patent: 0646648 (1995-04-01), None
patent: WO 01/85723 (2001-11-01), None
patent: WO 02/055495 (2002-07-01), None
patent: WO 03/007887 (2003-01-01), None
patent: WO 03/040107 (2003-05-01), None
patent: WO 03/063781 (2003-08-01), None
patent: WO 2004/007463 (2004-01-01), None
patent: WO 2004/094407 (2004-11-01), None
patent: WO 2005/009974 (2005-02-01), None
patent: WO 2005/040130 (2005-05-01), None
patent: WO 2005/063716 (2005-07-01), None
patent: WO 2005/095354 (2005-10-01), None
patent: WO 2007/120655 (2007-10-01), None
patent: WO 2007/120718 (2007-10-01), None
Zhu et al. Bioorganic & Medicinal Chemistry Letters, vol. 18, p. 4393-4396 (2008).
Little et al., Obesity Rev., vol. 6 (2005), pp. 297-306, “Role of cholecystokinin in appetite control and body weight regulation”.
Moran et al., Am. J. Physiol. Gastrointest. Liver Physiol., vol. 286 (2004), pp. G183-G188, “Gastrointestinal satiety signals”.
Lange et al., J. Med. Chem., vol. 48 (2005), pp. 1823-1838, “Bioisosteric replacements of the pyrazole moiety of rimonabant . . . ”.
Asproni et al., J. Med. Chem., vol. 48 (2005), pp. 2638-2645, “Synthesis, structure—activity relationships at the GABAA receptor in rat brain, . . .”.
Khanna et al., J. Med. Chem., vol. 40 (1997), pp. 1634-1647, “1,2-Diarylimidazoles as potent, cyclooxygenase-2 selective, and orally active antiinflarnmatory agents”.
Khanna et al., J. Med. Chem., vol. 43 (2000), pp. 3168-3185, “Selective cyclooxygenase-2 inhibitors: heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents”.
Asproni et al., J. Med. Chem., vol. 45 (2002), pp. 4655-4668, “Synthesis and pharmacological evaluation of 1-[(1,2-Diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines . . .”.
Szewczyk et al., Curr. Topics in Med. Chem., vol. 3 (2003), pp. 837-854, “CCK1R agonists: a promising target for the pharmacological treatment of obesity”.
Varga et al., Br. J. Pharmacol., vol. 141 (2004), pp. 1275-1284, “Involvement of endogenous CCK and CCK1 receptors in colonic motor function”.
Berger Richard
Edmondson Scott
Hansen Alexa
Zhu Cheng
Bernhardt Emily
Brown Baerbel R.
Merck Sharp & Dohme Corp.
Todaro John C.
LandOfFree
Substituted imidazole 4-carboxamides as cholecystokinin-1... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted imidazole 4-carboxamides as cholecystokinin-1..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted imidazole 4-carboxamides as cholecystokinin-1... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4175663